

## CYP-004 Osteoarthritis Trial Results

**Melbourne, Australia; 19 June 2026:** [Cynata Therapeutics Limited](#) (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, has received top-line results from the University of Sydney’s Phase 3 SCUpTOR<sup>1</sup> trial of CYP-004 in patients with osteoarthritis of the knee.

### Key findings:

- There were no safety concerns identified, with a similar adverse event profile between groups.
- There were no statistically significant differences between the active and control groups in either of the co-primary endpoints:
  - The proportion of participants reaching the patient-acceptable symptom state (PASS) threshold for knee pain at 24 months was 51.7% in the active group compared to 48.1% in the control group (p=0.5907).
  - There was a mean loss of central medial femorotibial (cMFT) cartilage thickness of 0.27mm in the active group compared to 0.21mm in the control group (p=0.1453).
- There was a substantial and durable reduction in knee pain intensity at all timepoints from 3-24 months compared to baseline (secondary endpoint), with an average reduction in pain score of 26.8/100 in the active group and 25.3/100 in the control group after 24 months. However, there were no significant differences between groups at any timepoint.

Analysis of additional outcome measures is ongoing and will be reported in due course.

CYP-004 is Cynata’s Cymerus™ off-the-shelf iPSC<sup>2</sup>-derived MSC<sup>3</sup> product candidate for intra-articular injection.<sup>4</sup> The SCUpTOR trial was a randomised and placebo-controlled Phase 3 trial, conducted by the University of Sydney, with funding provided under an Australian Government NHMRC<sup>5</sup> project grant. Patients were randomised to receive intra-articular injections of either saline (placebo control group) or CYP-004 (active group). The trial was led by Professor David Hunter, the Florance and Cope Chair of Rheumatology and Professor of Medicine at the University of Sydney and Royal North Shore Hospital.

### Dr Kilian Kelly, Cynata’s CEO and Managing Director, said:

*“The results of this trial are disappointing. The pain reduction in the control group was much better than expected: the study design assumed that 35% of control patients would reach the PASS threshold, but it has turned out that almost 50% have done so. The pain reduction in the active group was in line with our expectations, but unfortunately there is no evidence of a reduction in cartilage loss. We would like to thank Professor Hunter and the rest of the study team for conducting the trial, as well as the patients who participated.”*

In light of these outcomes, following the recently announced results of the Phase 2 clinical trial of CYP-001 in patients with acute graft versus host disease (see [announcement dated 17 June 2026](#)), the Company is now actively reviewing options for further development of the Cymerus™ technology, and will provide an update as soon as possible.

### Investor Webinar

An investor webinar will be held on Monday 22 June 2026, at 8:30am AEST, hosted by CEO and Managing Director, Dr Kilian Kelly, and Chair, Dr Geoff Brooke. Please visit the following link to register: <https://cynata.com/webinars/rvJo2r-cynata-investor-webinar>

**-ENDS-**

**Authorised for release by Dr Kilian Kelly, CEO & Managing Director**



**CONTACTS:** Dr Kilian Kelly, CEO & MD, Cynata Therapeutics, +61 (03) 7067 6940, [kilian.kelly@cynata.com](mailto:kilian.kelly@cynata.com)  
Lauren Nowak, Media Contact, +61 (0)400 434 299, [investors@cynata.com](mailto:investors@cynata.com)

#### **About Cynata Therapeutics (ASX: CYP)**

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges and limitations of conventional MSC production by using induced pluripotent stem cells (iPSCs) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the necessity to obtain tissue from multiple donors on an ongoing basis, and without the complexity and product inconsistency resulting from conventional methods.

**Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, [Automic Group](#).**

---

<sup>1</sup> SCUpTOR = Stem Cells as a symptom- and strUcture-modifying Treatment for medial tibiofemoral OsteoaRthritis. Further details on the trial can be found here: <https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12620000870954>.

<sup>2</sup> iPSC = induced pluripotent stem cell

<sup>3</sup> MSC = mesenchymal stem (or stromal) cell

<sup>4</sup> Intra-articular injection = injection into a joint

<sup>5</sup> NHMRC = National Health and Medical Research Council